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Background: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic
acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report
presents an updated and final survival analysis with BRAF and extended RAS mutational status, 5 years after the primary analysis.
Methods: A total of 566 patients were included in the intention-to-treat (ITT) population of the NORDIC-VII study. Updated survival
status was obtained from 176 patients who were alive in the primary survival analyses. Samples from 223 tumours previously found to
be KRAS (exon 2) and BRAF (V600E) wild-type, were re-analysed for KRAS (exons 3 and 4) and NRAS (exons 2–4) mutations.
Results: Including the extended RAS analyses, RAS and BRAF mutational status was available from 457 patients (81% of the ITT
population). RAS was mutated in 46% and BRAF in 12% of the tumours. RAS and BRAF, if mutated, were negative prognostic
factors. The updated analyses confirmed the finding of the primary report that cetuximab did not provide any additional benefit
when added to FLOX in patients with RAS/BRAF wild-type tumours, neither on progression-free nor overall survival. However, the
outcomes in a subset of patients, which, after the first eight treatment cycles, received cetuximab alone, suggested a beneficial
effect of cetuximab monotherapy.
Conclusions: Adding cetuximab to Nordic FLOX did not provide any clinical benefit, but the data suggested an effect of
cetuximab monotherapy in patients with RAS/BRAF wild-type tumours in the NORDIC-VII cohort. The data were compatible with a
negative interaction between cetuximab and the Nordic FLOX chemotherapy backbone.
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Several studies have shown that adding EGFR antibodies to
chemotherapy in first-line treatment of metastatic colorectal cancer
(mCRC) improves outcome (Bokemeyer et al, 2009; Van Cutsem
et al, 2009; Douillard et al, 2010). Initially, the effect was reported
to be restricted to patients with KRAS (exon 2) wild-type tumours.
Extended RAS analyses have demonstrated lack of response to
EGFR antibodies also in patients with tumours harbouring other
KRAS (exons 3 and 4) or NRAS mutations (Douillard et al, 2013;
Bokemeyer et al, 2015; Van Cutsem et al, 2015).
The NORDIC-VII study (Tveit et al, 2012), randomised phase
III trial, investigated the effect of adding cetuximab to a regimen of
bolus 5-fluorouracil (5-FU)/folinic acid (FA) and oxaliplatin (Nordic
FLOX) in first-line therapy of mCRC (Sorbye et al, 2004). In the
intention-to-treat (ITT) population of 566 patients there was no
statistically significant difference in overall response rate (ORR),
progression-free survival (PFS), or overall survival (OS) between the
treatment arms, and no effect of adding cetuximab to Nordic FLOX
was demonstrated in patients with KRAS (exon 2) wild-type tumours
(Tveit et al, 2012). These results were unexpected, however, the
COIN trial also showed lack of effect when adding cetuximab to an
oxaliplatin–capecitabine regimen in KRAS wild-type cases, while
combination of cetuximab with the commonly used FOLFOX
regimen gave a minor benefit (Maughan et al, 2011). Theoretically,
the lack of effect of cetuximab in NORDIC-VII might have at least
two explanations, a negative influence of the companion chemother-
apy regimen used or a patient population in this study that was non-
responsive to anti-EGFR antibodies. On the basis of the results
of a bolus 5-FU/FA regimen in the NORDIC-VII study, and the
majority of patients in the COIN trial who received capecitabine,
it has been suggested that when an EGFR antibody is added to
fluoropyrimidine–oxaliplatin chemotherapy, the type of fluoropyr-
imidine regimen may influence treatment outcome (Grothey and
Lenz, 2012; Mahipal and Grothey, 2016).
An updated OS analysis of NORDIC-VII is reported here, 5
years after the primary survival analysis. The impact of RAS (KRAS
exons, 2, 3, and 4, and NRAS exons 2, 3, and 4) and BRAF (V600E)
mutation status on prognosis and treatment outcome was
investigated. Moreover, to investigate whether cetuximab might
have an effect when given alone also in this patient population, we
have examined the outcome in patients who received cetuximab in
the absence of FLOX as maintenance therapy after eight cycles of
treatment.
MATERIALS AND METHODS
Study design, treatments, and data collection. The NORDIC-VII
study is a randomised phase III trial investigating the effect of
adding cetuximab to the Nordic FLOX regimen of bolus 5-FU/FA
and oxaliplatin in previously untreated patients with mCRC.
Patients were randomly assigned to receive FLOX (arm A),
cetuximab plus FLOX (arm B), or continuous cetuximab combined
with intermittent FLOX (arm C). In arms A and B, treatment was
continued until progressive disease (PD) or unacceptable toxicity.
In arm C, FLOX was usually stopped after eight courses (16 weeks
of treatment), and in cases of objective response or stable disease,
cetuximab was continued as maintenance therapy. After recording
PD in arm C, FLOX was reintroduced and continued together with
cetuximab until PD or unacceptable toxicity (Tveit et al, 2012).
Between May 2005 and October 2007, 571 patients from 32 centres
were enrolled in the study and 566 were evaluable in the ITT
population. In the primary report, patients were followed for PFS
and OS analyses up to 12 and 18 months, respectively, after
inclusion of the last patient (Tveit et al, 2012).
Updated OS data were obtained from 176 out of 182 patients
reported alive in the primary analysis. The updated OS analysis
had censoring date 30 April 2014. Four patients (three in arm A
and one in arm C) were lost to follow-up and two had withdrawn
their consent before the primary analysis, and for these the
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Figure 1. CONSORT diagram of the study design.
BRITISH JOURNAL OF CANCER Cetuximab in metastatic colorectal cancer
1272 www.bjcancer.com |DOI:10.1038/bjc.2017.93
censoring date was the last date they were known to be alive and
not withdrawn (Figure 1).
Mutation analysis of KRAS, NRAS, and BRAF. In the primary
analysis, KRAS (exon 2) mutation status was available for 498
patients. From this cohort with known KRAS (exon 2, codons
G12D, G12A, G12V, G12S, G12C, G12R, and codon G13D) and
BRAF (exon 15, V600E) mutation status, tumour DNA of 457
patients (81% of the ITT population) was available for extended
RAS mutation testing. In all, 179 patients (39%) had tumours with
known KRAS (exon 2) mutations, and 55 (12%) had tumours with
BRAF mutation. As KRAS and BRAF mutations were considered to
be mutually exclusive (Rajagopalan et al, 2002), tumour DNA from
the remaining 223 KRAS (exon 2)/BRAF wild-type patients was
analysed for the other KRAS mutations (in exons 3 and 4) and
NRAS mutations (in exons 2, 3, and 4).
Tumour DNA extraction from formalin-fixed, paraffin-
embedded (FFPE) tumour tissue and analyses of mutations in
KRAS (exon 2) and BRAF have been previously reported (Tveit
et al, 2012). DNA was screened for the presence of the KRAS
mutations Q61H, Q61L, and Q61R in exon 3, and K117X (K117N
351A4C, K117N 351A4T, and K117R, K117E) and A146X
(A146T, A146P, and A146V) in exon 4, using the KRAS Mutation
Analysis Kit for Real-Time PCR (exons 2, 3, and 4) by EntroGen
(Woodland Hills, CA, USA). The NRAS mutations G12C, G12D,
G12S, G13V, G13R, Q61K, Q61R, Q61L, Q61H, and A146T in
exons 2, 3, and 4 were analysed using the NRAS Mutation Analysis
Kit (EntroGen). The mutation detection assays and the analysis of
the results were done in accordance with the manufacturer’s
instructions. Input in the KRAS (exons 3 and 4) and NRAS assays
were 10 and 20 ng of whole-genome DNA from FFPE material,
respectively.
Ethics. The NORDIC-VII study (http://clinicaltrials.gov/show/
NCT00145314) was approved by the national ethics committees
and governmental authorities in each country and conducted in
accordance with the Declaration of Helsinki. All patients had
provided written informed consent.
Statistical analysis. The statistical analyses, using IBM SPSS
(version 23, IBM Corp., Armonk, NY, USA), were performed in
the ITT population and in subsets of patients based on RAS and
BRAF mutation status. Demographic data were described with
median and range (continuous variables) and proportions and
Table 1. Baseline patient demographics and clinical characteristics
Study population
ITT
RAS/
BRAF
status
unknown Tested for RAS and BRAF mutations RAS/BRAF wild-type
Total
(n¼566)
Total
(n¼109)
Total
(n¼457)
Arm A
(n¼146)
Arm B
(n¼158)
Arm C
(n¼153)
Total
(n¼192)
Arm A
(n¼64)
Arm B
(n¼66)
Arm C
(n¼62)
Age (years)
Median (range) 62 (24–75) 62 (30–75) 62 (24–75) 60 (35–75) 61 (24–74) 64 (33–75) 62 (24–75) 60 (40–75) 60 (24–74) 65 (36–75)
Gender, n (%)
Male 334 (59) 61 (56) 273 (60) 80 (55) 98 (62) 95 (62) 126 (66) 30 (47) 51 (77) 45 (73)
Female 232 (41) 48 (44) 184 (40) 66 (45) 60 (38) 58 (38) 66 (34) 34 (53) 15 (23) 17 (27)
WHO PS, n (%)
0 380 (67) 73 (67) 307 (67) 102 (70) 108 (68) 97 (63) 129 (67) 48 (75) 44 (67) 37 (60)
1 162 (29) 32 (29) 130 (28) 38 (26) 44 (28) 48 (31) 54 (28) 11 (17) 19 (29) 24 (39)
2 24 (4) 4 (4) 20 (4) 6 (4) 6 (4) 8 (5) 9 (5) 5 (8) 3 (5) 1 (2)
Site of primary tumour, n (%)
Colon 333 (59) 58 (53) 275 (60) 83 (57) 91 (58) 101 (66) 111 (58) 36 (56) 33 (50) 42 (68)
Rectum 233 (41) 51 (47) 182 (40) 63 (43) 67 (42) 52 (34) 81 (42) 28 (44) 33 (50) 20 (32)
Previous treatment, n (%)
Primary tumour resected 382 (68) 35 (32) 347 (76) 114 (78) 118 (75) 115 (75) 146 (76) 51 (80) 49 (74) 46 (74)
Adjuvant chemotherapy 51 (9) 5 (5) 46 (10) 14 (10) 16 (10) 16 (11) 21 (11) 6 (9) 9 (14) 6 (10)
Preoperative radiotherapy 80 (14) 10 (9) 70 (15) 18 (12) 29 (18) 23 (15) 29 (15) 6 (9) 17 (26) 6 (10)
Timing of metastases, n (%)
Synchronous 402 (71) 94 (86) 308 (67) 97 (66) 106 (67) 105 (69) 129 (67) 43 (67) 45 (68) 41 (66)
Metachronous 164 (29) 15 (14) 149 (33) 49 (34) 52 (33) 48 (31) 63 (33) 21 (33) 21 (32) 21 (34)
Number of metastatic sites, n (%)
1 site 162 (29) 26 (24) 136 (30) 44 (30) 53 (34) 39 (26) 67 (35) 24 (38) 23 (35) 20 (32)
41 sites 404 (71) 83 (76) 321 (70) 102 (70) 105 (67) 114 (75) 125 (65) 40 (63) 43 (65) 42 (68)
Type of metastases, n (%)
Liver only 107 (19) 17 (16) 90 (20) 31 (21) 34 (22) 25 (16) 53 (28) 19 (29) 17 (26) 17 (27)
Liver plus other 312 (55) 69 (63) 243 (53) 69 (47) 76 (48) 98 (64) 92 (48) 25 (39) 31 (47) 36 (58)
Non-liver 147 (26) 23 (21) 124 (27) 46 (32) 48 (30) 30 (20) 47 (25) 20 (31) 18 (27) 9 (15)
Investigations, n (%)
Normal alkaline
phosphatase level
298 (53) 48 (44) 250 (55) 86 (59) 82 (52) 82 (54) 100 (52) 38 (59) 34 (52) 28 (45)
Platelet count o400 nl1 398 (70) 70 (64) 328 (72) 100 (69) 115 (73) 113 (74) 142 (74) 45 (70) 51 (77) 46 (74)
White blood cell count
o10nl1
428 (76) 69 (63) 359 (79) 118 (81) 123 (78) 118 (77) 152 (79) 51 (80) 53 (80) 48 (77)
Abbreviations: ITT¼ intention to treat; PS¼performance status; WHO¼World Health Organisation.
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percentages (categorical variables). The PFS and OS were
compared between treatment groups using the log-rank test, and
treatment effects were estimated using Kaplan–Meier plots and
Cox proportional hazards model. Separate univariable analyses of
the effect of the WHO performance status, alkaline phosphatase
(ALP), and RAS and BRAF mutation status were performed. Only
variables statistically significant in univariable analyses were
included in the multivariable analyses, and models were thereafter
restricted to include statistically significant variables only.
RESULTS
Patients. In all, 566 patients were evaluable and included in the
ITT population in the primary analysis of the NORDIC-VII study.
Baseline characteristics were well balanced between the three
treatment arms (Tveit et al, 2012). In the present study of 457
patients with available results for RAS and BRAF mutation status,
the patient groups were well balanced and representative for the
ITT population (Table 1 and Supplementary Table S1).
Updated OS. The median OS for the overall ITT population
(n¼ 566) was 20.1 months, and there was no statistically
significant difference between the treatment arms (Figure 2A). In
all, 38 out of 44 censored patients were registered alive in the
updated analysis, 12 (7%), 21 (11%), and 5 (3%) in arm A, B, and
C, respectively. Of the 38 patients reported alive, 18 (47%) had
stopped study treatment due to secondary complete surgical
resection of metastases, 5 of 12 in arm A, 11 of 21 in arm B, and 2
of 5 in arm C.
Extended RAS and BRAF mutations. The mutation analyses are
reported in Table 2. In the cohort of 457 patients, 210 (46%) had
tumours with (any) RAS mutations, 55 (12%) had BRAF mutation,
and 192 (42%) were RAS/BRAF wild-type. The frequency and
distribution of RAS and BRAF mutations were similar in the three
treatment arms A, B, and C, with any RAS mutations in 63 (43%),
72 (46%), and 75 (49%), respectively, and BRAF mutations in 19
(13%), 20 (13%), and 16 (10%), respectively.
Survival related to RAS and BRAF mutation status. The patient
population with known RAS and BRAF mutation status had almost
identical OS compared to the ITT population (Figure 2B), and, as
shown in Figure 2C, there was no statistically significant difference
between the treatment arms in patients with RAS/BRAF wild-type
tumours (27.3, 23.5, and 23.7 months, respectively). These data are
1.0
0.8
0.6
0.4
0.2
0
A B
C D
1.0
0.8
0.6
0.4
0.2
Time (months)
3624120 48 60 72 84 96
O
ve
ra
ll s
ur
viv
al
(pr
ob
ab
ilit
y)
1.0
0.8
0.6
0.4
0.2
Time (months)
3624120 48 60 72 84 96
Time (months)
362412 48 60 72 84 96
B vs A: HR = 0.92 (95% CI, 0.74 – 1.14), P = 0.43
C vs A: HR = 1.09 (95% CI, 0.88 – 1.34), P = 0.45
RAS Mut vs RAS/BRAF WT: 
HR = 1.26 (95% CI, 1.02 – 1.55), P = 0.03
BRAF Mut vs RAS/RAF WT: 
HR = 2.70 (95% CI, 1.98 – 3.67), P < 0.001
No. at risk
Arm A
Arm B
Arm C
185
194
187
19.7173 (89)Arm B (15.9–23.5) 20.1141 (89)Arm B (15.2–25.0)
20.3180 (96)Arm C (17.1–23.5) 20.5147 (96)Arm C (17.1–23.9)
20.4169 (91)Arm A (16.8–23.9) 20.5133 (91)Arm A (16.8–24.3)
B vs A: HR = 0.95 (95% CI, 0.75 – 1.20), P = 0.66
C vs A: HR = 1.14 (95% CI, 0.90 – 1.44), P = 0.28
Total
population 522 (92) 20.1 (18.0–22.3)
Total 
population 421 (92) 20.5 (18.1–22.9)
No. at risk
Arm A
Arm B
Arm C
146
158
153
No. at risk
Events
n (%)
Median
Months (95% CI)
Events
n (%)
Median
Months (95% CI)
Events
n (%)
Median
Months (95% CI)
135 81 45 27 18 15 9 2
143 81 50 36 28 25 15 6
133 79 40 25 13 8 7 2
112 65 2439 15 13 8 2
117 67 43 32 21 12 524
111 64 32 22 11 7 6 2
RAS Mut 210 165 86 45 31 16 15 11 4
RAS/BRAF WT 192 158 100 65 43 31 24 13 5
O
ve
ra
ll s
ur
viv
al
(pr
ob
ab
ilit
y)
O
ve
ra
ll s
ur
viv
al
(pr
ob
ab
ilit
y)
O
ve
ra
ll s
ur
viv
al
(pr
ob
ab
ilit
y)
1.0
0.8
0.6
0.4
0.2
0
Time (months)
362412 48 60 72 84 96
Events
n
Median
(95% CI)
B vs A: HR = 1.07 (95% CI, 0.74 – 1.55), P = 0.70
C vs A: HR = 1.38 (95% CI, 0.95 – 1.98), P = 0.09
No. at risk
24.6174 (91)RAS/BRAF WT (21.1–28.1)Arm A (18.4–36.2)56 (88) 27.3
20.3193 (92)RAS Mut (17.1–23.5)Arm B (17.1–29.9)58 (88) 23.5
9.554 (98)BRAF Mut (7.2–11.8) Arm C (15.8–31.5)60 (97) 23.7
Arm A 64 55 36 25 16 12 10 5 1
Arm B 66 55 33 23 17 13 11 6 3
Arm C 62 48 31 17 10 6 3 2 1
(%)
BRAF Mut 55 17 10 4 4 3 2 2 –
Months
Figure 2. Survival curves. Overall survival in the three different treatment arms: (A) intention-to-treat population; (B) RAS- and BRAF-tested
population; and (C) RAS and BRAF wild-type population. (D) Overall survival in patients with RAS and BRAF wild-type, RAS mutant, and BRAF-
mutated tumours. CI = confidence interval; HR=hazard ratio; Mut=mutation; WT=wild-type.
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in agreement with the previously published findings (Tveit et al,
2012).
Prognostic value of RAS and BRAF mutations. The outcome in
the patients, depending on the mutational status of their tumours,
is shown in Figure 2D. The median OS for those with RAS/BRAF
wild-type tumours was 24.6 months, while it was shorter for those
with tumours harbouring mutations in RAS (20.3 months) and,
particularly, in patients with BRAF-mutated tumours (9.5 months).
The prognostic value of RAS or BRAF mutation was further
demonstrated in a Cox regression model for OS, which included
the WHO performance status and ALP level registered before start
of treatment as explanatory variables. Similar results were obtained
when OS was censored at start of treatment with EGFR antibodies
as second- or third-line therapy (Supplementary Table S2).
Response rates and PFS related to RAS and BRAF mutation
status. Confirmed ORR values in the ITT population, the RAS- and
BRAF-tested population, and subgroups by mutation status are listed
in Supplementary Table S3. Numerically, ORR was highest in
patients with RAS/BRAF wild-type tumours, and in this cohort ORR
was somewhat higher (not statistically significant) for patients in arm
B (61%) or arm C (60%), compared to those in arm A (50%).
The median PFS was 8.3, 8.2, and 7.4 months for arms A, B, and
C, respectively, in the population with known RAS and BRAF
mutation status (Figure 3A). In patients with RAS/BRAF wild-type
tumours, the curves for arms A, B, and C were similar, with median
PFS of 9.3, 9.5, and 9.2 months, respectively (Figure 3B). In patients
with RAS mutant tumours, there was no statistically significant
difference between the median PFS of 8.3 months in arm B
compared to 7.9 months in arm A (HR, 0.84 (0.59–1.19); P¼ 0.32).
Progression-free survival in patients treated with cetuximab in
the absence of FLOX. From the start of treatment, patients in arm
A were randomised to receive FLOX, while those in both arms B
and C received cetuximab plus FLOX. After eight cycles of
chemotherapy (B16 weeks of treatment), the patients in arm C
were treated with cetuximab only, while those in arm A continued
the therapy with FLOX. This fact allowed a comparison of the
outcome of cetuximab monotherapy with FLOX treatment from
cycle 9 of 159 patients with known RAS and BRAF mutation status.
Progression-free survival was calculated from the start of cycle 9 to
event (progression or death) or censoring. Figure 3C shows that for
patients with RAS/BRAF wild-type tumours the outcome in arm A
and C was closely similar, 5.8 vs 6.3 months. In contrast, for
patients with RAS-mutated tumours, PFS was markedly shorter in
those receiving cetuximab monotherapy (arm C) compared to
patients treated with FLOX (arm A), 2.3 vs 4.4 months (P¼ 0.003,
Figure 3D). There was a positive interaction between treatment
arms, A and C, and RAS/BRAF mutation status (P¼ 0.046)
Third-line treatment with EGFR antibodies. Figure 4 shows the
treatment outcome of 82 patients with known RAS and BRAF
mutation status who received therapy with EGFR antibodies
(cetuximab or panitumumab) as second- or third-line therapy after
end of treatment in NORDIC-VII. The patients with RAS/BRAF wild-
type tumours had a median survival of 10.1 months from start of
later-line treatment with EGFR antibodies, while the median survival
of patients with RAS or BRAF mutant tumours was 6.6 months.
Colon vs rectum. Outcome stratified on the origin of primary
tumour was examined (Supplementary Table S4). In the ITT
population, patients with colon cancer had shorter median OS
compared to those with their primary tumour in rectum, 18.6 vs 22.3
months (HR, 0.83 (0.70–0.99); P¼ 0.04). A similar trend was
observed in subpopulations based on RAS/BRAF mutation status.
There was no statistically significant difference in PFS or OS between
the treatment arms neither in colon nor in rectal cancer. Location of
primary tumour within colon was not registered in this study.
DISCUSSION
The updated survival analysis showed no statistically significant
difference between OS for the three treatment arms, in the ITT,
RAS/BRAF tested, or RAS/BRAF double wild-type populations.
Similarly, in the population of patients with known RAS and BRAF
mutation status and in patients with RAS/BRAF double wild-type
tumours, there was no statistically significant difference in PFS
between the treatment arms. However, in arm B there was a
numerically higher number of long-term survivors and a higher
number of patients with complete surgical resection of metastases.
In the primary analysis of NORDIC-VII an unexpected trend
towards increased PFS was found in patients with tumours
harbouring KRAS (exon 2) mutations who received FLOX plus
cetuximab, as compared to FLOX alone (arm B vs arm A). This
difference in PFS was less pronounced in analyses based on the
extended RAS mutation status, further suggesting that the
previously reported result was an incidental finding. Taken
together, the analyses based on RAS status and updated survival
data did not change the conclusion from the primary report that
cetuximab did not add any significant benefit to the Nordic FLOX
regimen in first-line treatment of mCRC (Tveit et al, 2012).
Patients with colon cancer had shorter median OS compared to
those with rectal cancer, in line with other trials (Tejpar et al,
2017). Recently, pooled data from two randomised phase III trials
have emphasised that clinical benefit of cetuximab treatment is
significantly higher in patients with left-sided colon and rectum
tumours compared to right-sided (Tejpar et al, 2017). Precise
location of the primary tumour within colon was not registered in
this study, and as no effect of adding cetuximab to FLOX was
observed in the population of colon or rectal cancer patients in
NORDIC-VII, a possible difference in outcome between right and
left colon cancer was not further examined.
Table 2. RAS and BRAF mutation status
Study population
Genotype
Total
(n¼457)
n (%)
Arm A
(n¼146)
n (%)
Arm B
(n¼158)
n (%)
Arm C
(n¼153)
n (%)
Wild-type (RAS and
BRAF)
192 (42.0) 64 (43.8) 66 (41.8) 62 (40.5)
RAS mutant 210 (46.0) 63 (43.2) 72 (45.6) 75 (49.0)
KRAS exon 2 mutant 179 (39.2) 55 (37.7) 67 (42.4) 57 (37.3)
KRAS G12A 16 (3.5) 5 (3.4) 5 (3.2) 6 (3.9)
KRAS G12R 3 (0.7) 1 (0.7) 1 (0.6) 1 (0.7)
KRAS G12D 62 (13.6) 14 (9.6) 27 (17.1) 21 (13.7)
KRAS G12C 16 (3.5) 4 (2.7) 7 (4.4) 5 (3.3)
KRAS G12S 11 (2.4) 5 (3.4) 4 (2.5) 2 (1.3)
KRAS G12V 30 (6.6) 11 (7.5) 11(7.0) 8 (5.2)
KRAS G13D 41 (9.0) 15 (10.3) 12 (7.6) 14 (9.2)
KRAS exon 3 mutant 9 (2.0) 2 (1.4) 2 (1.3) 5 (3.3)
KRAS Q61H 3 (0.7) 0 1 (0.6) 2 (1.3)
KRAS Q61L 5 (1.1) 2 (1.4) 1 (0.6) 2 (1.3)
KRAS Q61R 1 (0.2) 0 0 1 (0.7)
KRAS exon 4 mutant 7 (1.5) 2 (1.4) 1 (0.6) 4 (2.6)
KRAS K117X 1 (0.2) 0 0 1 (0.7)
KRAS A146X 6 (1.3) 2 (1.4) 1 (0.6) 3 (2.0)
NRAS exon 2 mutant 8 (1.8) 2 (1.4) 1 (0.6) 5 (3.3)
NRAS G12S 1 (0.2) 1 (0.7) 0 0
NRAS G12C 6 (1.3) 0 1 (0.6) 5 (3.3)
NRAS G13V 1 (0.2) 1 (0.7) 0 0
NRAS exon 3 mutant 7 (1.5) 2 (1.4) 1 (0.6) 4 (2.6)
NRAS Q61L 2 (0.4) 0 0 2 (1.3)
NRAS Q61K 3 (0.7) 1 (0.7) 1 (0.6) 1 (0.7)
NRAS Q61R 2 (0.4) 1 (0.7) 0 1 (0.7)
BRAF mutant (V600E) 55 (12.0) 19 (13.0) 20 (12.7) 16 (10.5)
Cetuximab in metastatic colorectal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.93 1275
The frequency of the RAS mutations was in agreement with
those reported in other trials (Douillard et al, 2013; Bokemeyer
et al, 2015; Van Cutsem et al, 2015), and patients with tumours
harbouring RAS or BRAF mutations showed impaired outcomes
compared to those with RAS/BRAF wild-type tumours, also in line
with results reported from recent first-line chemotherapy trials in
mCRC (Maughan et al, 2011; Cremolini et al, 2015). Thus, it is
unlikely that the reason for lack of effect of cetuximab in this trial
was that the NORDIC-VII cohort differed fundamentally from
other patient populations studied.
After eight cycles of chemotherapy, the patients in arm C were
treated with cetuximab only, while those in arm A continued the
therapy with FLOX. This study design allowed a comparison of
cetuximab monotherapy with FLOX treatment from cycle 9. In
patients with double wild-type tumours the PFS from cycle 9 was
quite similar for the patients receiving FLOX (arm A) and those
treated with cetuximab only (arm C). In contrast, in patients with
RAS-mutated tumours, the PFS was significantly reduced in those
who received cetuximab monotherapy compared with FLOX. On
the basis of the assumption that chemotherapy (FLOX) received
from cycle 9 improved the outcome in patients with RAS/BRAF
wild-type as well as in RAS-mutated tumours, these results strongly
suggest that also for the NORDIC-VII cohort, in patients with
RAS/BRAF wild-type tumours, unlike RAS-mutated, cetuximab
may exert an effect as single agent. These results also suggest that
maintenance cetuximab therapy, as given in arm C, provides an
alternative approach to ongoing chemotherapy in the relevant
biomarker-selected group, in line with the results of the COIN-B
trial (Wasan et al, 2014).
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Figure 3. Survival curves. Progression-free survival in the three different treatment arms: (A) RAS- and BRAF-tested population; (B) RAS and BRAF wild-
type population. Progression-free survival from start of treatment cycle 9 in arms A (FLOX) and C (maintenance treatment with cetuximab) in patients
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To further elucidate the effects of anti-EGFR therapy in this
patient population, survival of patients who received such
therapy as part of second- or third-line treatment was analysed.
This treatment was mainly offered before the demonstration that
effect of EGFR antibodies was restricted to KRAS wild-type
tumours (Amado et al, 2008; Karapetis et al, 2008). Patients with
RAS/BRAF wild-type tumours, previously treated in NORDIC-
VII, had significantly longer median OS from start of this
treatment compared to those with RAS or BRAF mutations,
consistent with outcome reported by others (Amado et al, 2008;
Karapetis et al, 2008). These results are based on observational
data and should be interpreted with caution as RAS and BRAF
mutations affect prognosis and comparison with no EGFR
antibody therapy was not possible. However, it may be
hypothesised that a 3.5 month difference in median OS from
start of second- or third-line EGFR antibody therapy reflects
some effect of this treatment in the wild-type patients. The
prognosis reflected by the RAS/BRAF mutation status was
sustained in a Cox regression model where OS was censored at
start of second- or third-line treatment with EGFR antibodies if
the patients had received such treatment.
In view of the results of NORDIC-VII, together with the data
from COIN and the New EPOC trials (Maughan et al, 2011;
Primrose et al, 2014), as compared to trials where cetuximab was
combined with irinotecan-based regimens (Van Cutsem et al,
2009), it may be discussed whether cetuximab and oxaliplatin are
good partners. We have no clinical data to answer this question
directly. However, preclinical studies have mechanistically
demonstrated an antagonistic modulation of cetuximab on the
effect of oxaliplatin (Dahan et al, 2009; Santoro et al, 2015). It
should, however, be noted that in the TAILOR trial a signifi-
cant benefit in terms of ORR, PFS, and OS was reported with
the addition of cetuximab to FOLFOX (Qin et al, 2016). It has
been suggested that the type of fluoropyrimidine regimen has
influence on treatment outcome when an EGFR antibody is
added to fluoropyrimidine–oxaliplatin chemotherapy (Grothey
and Lenz, 2012), and so far, a benefit has only been demons-
trated with the FOLFOX regimen (Bokemeyer et al, 2009;
Douillard et al, 2010; Qin et al, 2016). In the NORDIC-VII
study, a bolus 5-FU/FA regimen was used, and in the COIN trial,
the majority of patients received capecitabine. Thus, there might
be a positive pharmacodynamic synergism between the anti-
EGFR antibodies and 5-FU administered via the FOLFOX
regimens (Harstrick et al, 1998; Skvortsov et al, 2008; Kim
et al, 2009 Bijnsdorp et al, 2010), which was not achieved when
the Nordic FLOX bolus regimen was used as the chemotherapy
backbone.
In conclusion, the patient population of NORDIC-VII seems
to be comparable with other cohorts of mCRC patients who
start first-line therapy. The lack of effect of cetuximab when
added to the Nordic FLOX regimen strengthens the notion
that this combination is not favourable and strongly suggests
a negative interaction between the FLOX regimen and
cetuximab.
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